Vol 9: Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer.Report as inadecuate



 Vol 9: Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer.


Vol 9: Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 9: Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer.
This article is from PLoS ONE, volume 9.AbstractIntroduction: The overall survival rate is good for lymph-node-negative breast cancer patients, but they still suffer from serious over- and some undertreatments. Prognostic and predictive gene signatures for node-negative breast cancer have a high number of genes related to proliferation. The prognostic value of gene sets from commercial gene-expression assays were compared with proliferation markers. Methods: Illumina WG6 mRNA microarray analysis was used to examine 94 fresh-frozen tumour samples from node-negative breast cancer patients. The patients were divided into low- and high-risk groups for distant metastasis based on the MammaPrint-related genes, and into low-, intermediate- and high-risk groups based on the recurrence score algorithm with genes included in Oncotype DX. These data were then compared to proliferation status, as measured by the mitotic activity index, the expressions of phosphohistone H3 PPH3, and Ki67. Results: Kaplan-Meier survival analysis for distant-metastasis-free survival revealed that patients with weak and strong PPH3 expressions had 14-year survival rates of 87% n = 45, and 65% n = 49, p = 0.014, respectively. Analysis of the MammaPrint classification resulted in 14-year survival rates of 80% n = 45 and 71% n = 49, p = 0.287 for patients with low and high risks of recurrence, respectively. The Oncotype DX categorization yielded 14-year survival rates of 83% n = 18, 79% n = 42 and 68% n = 34 for those in the low-, intermediate- and high-risk groups, respectively p = 0.52. Supervised hierarchical cluster analysis for distant-metastasis-free survival in the subgroup of patients with strong PPH3 expression revealed that the genes involved in Notch signalling and cell adhesion were expressed at higher levels in those patients with distant metastasis. Conclusion: This pilot study indicates that proliferation has greater prognostic value than the expressions of either MammaPrint- or Oncotype-DX-related genes. Furthermore, in the subgroup of patients with high proliferation, Notch signalling pathway genes appear to be expressed at higher levels in patients who develop distant metastasis.



Author: Jonsdottir, Kristin; Assmus, Jorg; Slewa, Aida; Gudlaugsson, Einar; Skaland, Ivar; Baak, Jan P. A.; Janssen, Emiel A. M.

Source: https://archive.org/







Related documents